Premium
The androgen receptor co‐activator CBP is up‐regulated following androgen withdrawal and is highly expressed in advanced prostate cancer
Author(s) -
Comuzzi Barbara,
Nemes Constanze,
Schmidt Stefan,
Jasarevic Zerina,
Lodde Michele,
Pycha Armin,
Bartsch Georg,
Offner Felix,
Culig Zoran,
Hobisch Alfred
Publication year - 2004
Publication title -
the journal of pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.964
H-Index - 184
eISSN - 1096-9896
pISSN - 0022-3417
DOI - 10.1002/path.1609
Subject(s) - androgen receptor , lncap , androgen , bicalutamide , endocrinology , medicine , prostate cancer , cancer research , dihydrotestosterone , biology , chemistry , hormone , cancer
The androgen receptor co‐activator CREB (cAMP‐response element binding protein)‐binding protein (CBP) enhances androgen receptor activity after stimulation by androgenic hormones and androgen receptor antagonists. The aim of the present study was to investigate the regulation of CBP expression by steroid and peptide hormones in prostate cancer. For this purpose, LNCaP cells were treated with the synthetic androgen methyltrienolone (R1881), epidermal growth factor, insulin‐like growth factor‐I or interleukin‐6 (IL‐6). CBP protein and mRNA expression were studied by western blotting and real‐time PCR, respectively. CBP expression was also investigated in tissue specimens obtained from 26 patients with therapy‐resistant carcinoma of the prostate. In LNCaP cells, CBP protein was down‐regulated by R1881 or IL‐6. The non‐steroidal anti‐androgen bicalutamide antagonized the effects of R1881 and the Janus kinase inhibitor AG 490 reversed the effects of IL‐6. In contrast, neither R1881 nor IL‐6 caused any effect on CBP expression in the PC‐3 cell line. In LNCaP cells, the inhibition of CBP expression by R1881 or IL‐6 was also observed at the mRNA level. CBP protein was detected in all 26 specimens by immunohistochemistry. The results suggest that up‐regulation of CBP during androgen ablation may be relevant to the failure of endocrine therapy in patients with prostate carcinoma. Copyright © 2004 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.